CBD has reduced affinity for CB receptors. It acts being an antagonist or partial antagonist at endogenous cannabinoid receptors (both equally CB1 and CB2 receptor forms and other G-protein-coupled receptors [GPCRs]) by inhibiting comprehensive binding of direct ligands, and could act principall